Last reviewed · How we verify
Sevre-Long™
Sevre-Long™ is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to regulate glucose metabolism.
Sevre-Long™ is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to regulate glucose metabolism. Used for Type 2 diabetes, Obesity.
At a glance
| Generic name | Sevre-Long™ |
|---|---|
| Sponsor | Mundipharma Medical Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By activating the GLP-1 receptor, Sevre-Long™ increases insulin secretion in response to high blood glucose levels, decreases glucagon secretion, and slows gastric emptying, thereby lowering blood glucose levels and promoting weight loss.
Approved indications
- Type 2 diabetes
- Obesity
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevre-Long™ CI brief — competitive landscape report
- Sevre-Long™ updates RSS · CI watch RSS
- Mundipharma Medical Company portfolio CI